Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EluNIR-PERL
- Development stage
- Unknown
- Lead developer
- Medinol
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Administration
- Percutaneous, Implant
01
Overview
EluNIR-PERL is a seventh-generation drug-eluting coronary stent (DES) system developed by Medinol for the treatment of coronary artery disease. The device consists of a cobalt-chromium (CoCr) framework with an elastomeric coating that facilitates the controlled, sustained release of ridaforolimus (a rapamycin analogue) to the vessel wall to inhibit neointimal hyperplasia and prevent restenosis. EluNIR-PERL is distinguished by its enhanced visualization features, including four radiopaque markers (two at each end of the stent) and a unique hybrid polymer-metal radiopaque catheter tip designed for precise placement during percutaneous coronary intervention (PCI). The system received FDA approval in October 2023 and CE Mark approval in June 2024.
- Brand names
- EluNIR-PERL
02
Targets
mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on EluNIR-PERL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EluNIR-PERL.